Solasia Pharma KK
TSE:4597
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
|
CN |
Solasia Pharma KK
Research & Development
Solasia Pharma KK
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Solasia Pharma KK
TSE:4597
|
Research & Development
-¥430m
|
CAGR 3-Years
21%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
SanBio Co Ltd
TSE:4592
|
Research & Development
-¥2.6B
|
CAGR 3-Years
26%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-7%
|
|
|
GNI Group Ltd
TSE:2160
|
Research & Development
-¥3.3B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-24%
|
|
|
PeptiDream Inc
TSE:4587
|
Research & Development
-¥4.6B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Takara Bio Inc
TSE:4974
|
Research & Development
-¥6.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-5%
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Solasia Pharma KK
Glance View
Solasia Pharma KK engages in the development, sale, import and export of pharmaceutical products and medical devices. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 77 full-time employees. The company went IPO on 2017-03-24. is a Japan-based pharmaceutical company. The firm is mainly engaged in the development, sale, importing and exporting of pharmaceutical products targeting commercialization in Japan, China and other Asian countries. The company focuses on commercializing assets in the oncology/hematology field, by developing products licensed from western pharmaceutical and biotech companies. The firm's main products include SP-01 Granisetron Transdermal Delivery System (Sancuso), SP-02 Darinaparsin (Zinapar, ZIO-101, and SP-03 Oral Medical Device (episil oral liquid).
See Also
What is Solasia Pharma KK's Research & Development?
Research & Development
-430m
JPY
Based on the financial report for Dec 31, 2025, Solasia Pharma KK's Research & Development amounts to -430m JPY.
What is Solasia Pharma KK's Research & Development growth rate?
Research & Development CAGR 5Y
26%
Over the last year, the Research & Development growth was -4%. The average annual Research & Development growth rates for Solasia Pharma KK have been 21% over the past three years , 26% over the past five years .
